Thomas Jefferson University Brightens the Future With Vaccine Research

Researchers at Thomas Jefferson University are working hard to develop vaccines in an effort to fight some of the world’s toughest viruses and cancers. Back in 2017, Thomas Jefferson University was awarded a $30 million five-year contract over a five-year period to research safe vaccination solutions. Since then, university researchers have been developing strategies to find life changing answers to these global issues.

Last week, researchers at Thomas Jefferson University announced they had positive results with a new vaccine. The vaccine targets glioblastoma, the most aggressive type of primary brain cancer that typically results in death within 12 to 15 months after diagnosis. This vaccine was found to slow cancer growth in glioblastoma cancer patients during early-stage trials.  This result is extremely encouraging for researchers as well as cancer patients, and scientists at Thomas Jefferson University look forward to moving into a phase II trial later this year. 

Additionally in vaccine development, scientists at Thomas Jefferson University are investigating a group of hemorrhagic fever viruses that have gruesomely taken lives in West Africa for years. During 2018, $4.8 million in funding from the National Institute of Health (NIH) was awarded to the university specifically in support of developing a vaccine for both Filovirus and Lassa fever, two devastating hemorrhagic fever viruses. (to the right: image of the Lassa virus)

By This media comes from the Centers for Disease Control and Prevention's Public Health Image Library (PHIL), with identification number #8700.Note: Not all PHIL images are public domain; be sure to check copyright status and credit authors and content providers., Public Domain, https://commons.wikimedia.org/w/index.php?curid=1882524

Ongoing research has so far been successful, and in October of 2018, University researchers developed a vaccine targeting both rabies and the Lassa fever virus that was found to be effective in animal trials. This finding brings hope that a human vaccination for the Lassa fever virus will soon be a reality. Another important recent result of their research is a new way to analyze immune protection testing for the Lassa fever virus without having to unethically expose people to the virus during the human trials phase.

The researchers at Thomas Jefferson University are continuing their work and are constantly moving closer to receiving desired results. Thomas Jefferson University has and will continue to promote groundbreaking life science research, tackling many issues in the health sciences. The university distributes the entirety of its $147 million in research and development funding to the life sciences. This spring, Biotechnology Calendar, Inc. will be hosting its 10^th annual BioResearch Product Faire^TM event at Thomas Jefferson University. As a product supplier, this is the place to connect with well-funded researchers and educate them on your innovative products that will help them move forward with their groundbreaking discoveries.

The BioResearch Product Faire™ Event at Thomas Jefferson University

May 10, 2019

Click here if you sell laboratory supplies and would like to receive information about this event.

Click here if you are a researcher wishing to attend this event.

Call us today at (530) 272-6675 for more information.